DailyIQ
Last updatedUpdating…

GEHC·GE HealthCare Technologies Inc.

$68.48
-0.31 (-0.45%)
After Hours
High
$69.51
Open
$68.92
Market Cap
31.07B
52W High
$89.77
Low
$67.66
P. Close
$68.48
P/E
15.65
52W Low
$58.75
Fwd P/E
12.72
DailyIQ Est.
$84.78
Inst. Ownership
41.8%
Short Interest
4.10%
Days to Cover
4.7
Div. Yield
0.20%
Next Ex-Div
~Oct 23
Technical Score (1D)
24
BEARISH
News Sentiment
37
BEARISH
On Oct 13, analysts reported that GE HealthCare’s organic revenue growth had decelerated, indicating waning demand for its core imaging and diagnostics products. They noted that competitive pressure and a lack of new product launches were limiting the company’s upside potential. The consensus from market observers remained cautious regarding GEHC shares. The report suggested that the company’s prospects were constrained by these factors. As a result, analysts advised a cautious stance toward the stock.
LOW TARGET
$70 +2.2%
2 analysts
MEAN TARGET
$83 +20.8%
15 analysts
HIGH TARGET
$96 +40.2%
13 analysts
PRICE RANGE
$70.00 - $96.00
SB / B / H / S / SS
8/11/9/1/1
DAILYIQ EST.
$84.78 (+23.8%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NMS
Country
United States
Symbol
GEHC
Description
GE HealthCare Technologies Inc. is a global leader in medical technology, specializing in diagnostic imaging, patient monitoring, and pharmaceutical diagnostics. The company's core business revolves around providing innovative products, services, and digital solutions designed to improve patient care across a range of clinical areas. GEHC's diverse portfolio includes advanced imaging systems like CT and MR scanners, ultrasound devices, and patient monitoring equipment. Furthermore, the company develops and markets pharmaceutical diagnostics, including contrast media and radiopharmaceuticals, that enhance the effectiveness of imaging procedures. Operating through four key segments, GE HealthCare Technologies Inc. is committed to advancing healthcare through technological innovation and comprehensive solutions.
Bought (1Y)
10,000 shares
$642K
Sold (1Y)
39,154 shares
$2.7M
Grogan William KChief Financial Officer
Award/Grant31,877 shares2026-09-14
Grogan William KChief Financial Officer
Award/Grant12,840 shares2026-09-14
Grogan William KChief Financial Officer
Award/Grant62,256 shares2026-09-14
Arduini Peter JPresident and CEO
Tax Withholding6,303 shares2026-09-03
Estrampes CatherineChief Commer. & Growth Officer
Tax Withholding508 shares2026-09-03
69/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
40.0%
Net Margin
10.1%
Revenue CAGR
4.1%
Current Ratio
1.37x
Debt / Equity
0.96x
Return on Equity
20.1%
Earnings Summary
GE HealthCare Technologies Inc. is a global leader in medical technology, delivering diagnostic imaging, patient monitoring, and pharmaceutical diagnostics across advanced imaging systems and radiopharmaceuticals, positioning it firmly within the healthcare medical devices sector. In the most recent quarters, GEHC posted EPS of $1.45 in Q4 2024, beating the $1.26338 estimate, and $1.07 in Q3 2025, slightly above the $1.04689 forecast, while revenue remained relatively flat, $5.319B in Q4 2024 versus $5.143B in Q3 2025, indicating a modest decline in top‑line growth; the company consistently beat earnings estimates in the last four quarters, though revenue growth has slowed from a 7.5% increase in Q2 2025 to a 1.4% decline in Q4 2025. Historically, GEHC has maintained a steady YoY revenue growth trajectory of roughly 5–6% over the past three years, with EPS consistently exceeding analyst expectations, demonstrating resilient profitability even when revenue momentum decelerates. Recent news highlights a $945 million acquisition of SOFIE Biosciences, aimed at expanding the U.S. radiopharmaceutical supply chain and adding low‑double‑digit growth to the radiopharma portfolio, a strategic move that could enhance future revenue and margin profiles; the deal is expected to close in 2027 and is projected to be accretive to adjusted EBIT and EPS.

EPS

EstBeatMiss
$0.84$1.01$1.18$1.35$1.52Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.21 - -
Q2'26$1.04$1.13+9.1%
Q1'26$1.05$0.99-5.7%
Q4'25$1.43$1.44+1.0%
Q3'25$1.05$1.07+2.2%
Q2'25$0.92$1.06+15.4%

Revenue

EstBeatMiss
$4.9B$5.1B$5.4B$5.6B$5.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.5B - -
Q2'26$5.4B$5.3B-1.4%
Q1'26$5.0B$5.1B+2.1%
Q4'25$5.7B$5.7B-0.4%
Q3'25 - $5.1B -
Q2'25 - $5.0B -

Market Data

GEHC Stock Snapshot

BEARISH24/100
$68.43−$0.05 (0.1%)
Market cap
31.07B
P/E ratio
15.7
Day range
$67.66 – $69.51
News sentiment
37/100 · Bearish
Analyst target
$82.70 (+20.9%)
Consensus
Buy · 30 analysts
52-week range+16.5% off low · -23.8% from high
$58.75$89.77
Price $68.43 DailyIQ Est. $84.78

GEHC is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into GEHC?

RICH

At today's price, GE HealthCare Technologies Inc. needs to grow free cash flow about 11.1% a year for the next 10 years to justify its valuation at a 8.48% cost of capital. Over its actual history it has compounded free cash flow at 0.4% a year, so the market is asking for 10.7 percentage points above its own delivered rate. On that basis GEHC looks priced above what its own growth record supports.

Implied FCF growth
11.1%
Historical FCF CAGR
0.4%
Growth gap
+10.7 pts
Verdict
RICH
Discount rate (WACC)
8.48%
Beta
0.98

Behaviour On Record

What GEHC's own history says about today's numbers

Realized volatility (21d)
23.5% 28th pct
Below its peak
-26.8%
vs 200-day average
-2.8%
Up days (1y)
50%

GE HealthCare Technologies Inc. is currently running 23.5% annualised volatility over the last 21 sessions. Measured against GEHC's own 4 years of daily returns rather than a market-wide average, that is the 28th percentile — on the quiet side for this stock, against a typical reading of 28.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GEHC is trading -26.8% below its running peak. Across 3 full years on file, its median worst-drawdown-in-a-year was -27.6%, and the deepest was -37.8% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -2.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 44th percentile — close to the gap it normally carries. Over the past year GEHC closed higher on 50% of sessions, and it is currently 3 sessions into a rising streak.

Overnight risk is measurable too: GEHC has opened more than 2% away from the prior close in 20 of 958 sessions (2.1% of the time), with the largest gaps running +6.6% and -6.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, GEHC moved an average of 2.3% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.5% and a largest of -2.8%.

All figures computed from 959 daily closes between 2022-12-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against GEHC's own 4-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GEHC's sector?

GE HealthCare Technologies Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for GEHC?

CallsPuts

For GE HealthCare Technologies Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.62), with at-the-money implied volatility around 54.4%. The options market is pricing roughly a ±3.4% move by that expiry — a range of about $63.41–$67.93.

Put/call ratio (2026-10-16)
0.62
ATM implied volatility
54.4%
Total open interest
12,110
Expected move by 2026-10-16
±3.4% ($63.41–$67.93)

Analyst Rating Changes

Are analysts turning bullish or bearish on GEHC?

BTIG most recently reiterated its rating on GE HealthCare Technologies Inc. to Buy on Oct 12, 2026 with a price target of $75 (from $79). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
BTIG — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$79 → $75
Oct 7, 2026BarclaysInitiatedOverweight$85
Oct 5, 2026CitigroupMaintainedNeutral$75 → $71
Oct 5, 2026NeedhamReiteratedBuy$93
Sep 22, 2026NeedhamInitiatedBuy$93
Sep 17, 2026BTIGReiteratedBuy$79
Aug 19, 2026BTIGReiteratedBuy$79
Jul 31, 2026UBSMaintainedNeutral$67 → $73
Jul 30, 2026CitigroupMaintainedNeutral$69 → $75
Jul 30, 2026Evercore ISI GroupMaintainedOutperform$80 → $84
Jul 30, 2026Wells FargoMaintainedOverweight$75 → $85
Jul 29, 2026BTIGMaintainedBuy$75 → $79

Peers & ETF holders

GEHC peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

37/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
GE HealthCare’s recent performance has prompted analysts to caution investors. The company’s organic revenue growth has slowed, indicating a potential decline in demand for its core imaging and diagnostics products. Despite a lower share price, the consensus remains that GEHC’s prospects are constrained by a lack of new product launches and competitive pressure. The outlook suggests limited upside potential in the near term, leading to a cautious stance from market observers.
What did this article say?
GE HealthCare announced a $945 million acquisition of SOFIE Biosciences, strengthening its precision‑medicine supply chain. The deal is expected to enhance long‑term growth, though it will not immediately boost earnings. Q2 results showed 3.5 % organic revenue growth, 11 % order growth, and a $23.9 B backlog that exceeds annual sales. GEHC reaffirmed its guidance and maintained a 13x earnings multiple, positioning the company for a valuation re‑rating.
What did this article say?
GE HealthCare (GEHC) scheduled the release of its third‑quarter 2026 financial results for October 28, 2026, ahead of market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day, with a replay available on its investor website. The announcement provides investors with the timing of the earnings report and related disclosures, but does not indicate any change in guidance or performance expectations.
What did this article say?
Barclays analyst Christopher Pasquale initiated coverage on GE HealthCare Technologies (NASDAQ:GEHC) on October 7, assigning an Overweight rating. The bank set a price target of $85 per share, signaling confidence in the company’s growth prospects. This move follows GEHC’s recent product launches and earnings beat, positioning the firm favorably within the medical technology sector.
What did this article say?
GE HealthCare Technologies Inc. announced a definitive $945 million cash purchase of SOFIE Biosciences, a U.S. contract manufacturing organization focused on PET radiopharmaceuticals. The deal will create a final‑mile supply chain in the United States and broaden GEHC’s presence in the growing radiopharmaceutical market. Management expects the acquisition to lift revenue growth, adjusted EBIT margin and earnings per share in the first full year after closing, which is projected for the first half of 2027 pending regulatory approval.
What did this article say?
GE Healthcare Technologies announced a $945 million cash purchase of Sofie Biosciences, a U.S. contract manufacturing organization for PET radiopharmaceuticals. The deal adds 15 CMO sites and 21 cyclotrons, giving GE Healthcare a U.S. production and distribution network for its radiopharmaceuticals. Sofie also provides U.S. rights to the phase‑3 FAPI‑74 tracer, which GE already holds outside the U.S. The acquisition is expected to enhance GE’s precision diagnostics portfolio and position the company for future commercialization of the tracer by 2029.
What did this article say?
GE HealthCare announced the acquisition of Sofie Biosciences for $945 million, adding 15 U.S. contract manufacturing sites and a theranostics-focused CDMO facility to its portfolio. The deal, expected to close in the first half of 2027, will broaden GE HealthCare’s presence in the radiopharmaceutical market and support the production of its existing F‑18 diagnostic agents, including Flyrcado. The transaction is an all‑cash purchase that enhances GE HealthCare’s ability to supply novel PET radiopharmaceuticals to patients across the United States.
What did this article say?
GE HealthCare announced it would acquire Sofie Biosciences for $945 million in an all‑cash deal expected to close in the first half of 2027. The purchase adds Sofie’s 15 U.S. contract manufacturing sites and its theranostics‑focused CDMO operations, expanding GE HealthCare’s footprint in the PET radiopharmaceutical market. Sofie already produces GE’s Flyrcado diagnostic agent, and the acquisition is intended to broaden access to novel radiopharmaceuticals for cancer and Alzheimer’s disease imaging.
What did this article say?
GE HealthCare Technologies announced on October 5 that it would acquire Sofie Biosciences for $945 million. The deal adds a PET radiopharmaceutical company to GE HealthCare’s pharmaceutical diagnostics unit, broadening its imaging‑agent portfolio. Sofie’s products are used in brain, heart, and cancer imaging, and the acquisition is expected to grow the unit’s revenue in the low double digits. The transaction expands GE HealthCare’s presence in the rapidly growing PET market and strengthens its end‑to‑end radiopharmaceutical capabilities.
What did this article say?
Citigroup analyst Joanne Wuensch lowered GE HealthCare Technologies’ price target from $75 to $71 while keeping a neutral rating. The downgrade reflects a reassessment of the company’s valuation relative to peers. The move signals a modest negative outlook for the stock, though no fundamental business changes were cited.

Technical Analysis

Real-time indicators across multiple timeframes

24
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $12.96B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy52,275,76711.58%$4.29B2026-01-29
BlackRock, Inc.▲ Buy37,467,8438.30%$2.40B2026-08-07
Invesco Ltd.▲ Buy18,296,3504.05%$1.17B2026-08-14
Harris Associates L P▼ Sell15,329,6643.39%$981.25M2026-08-14
Geode Capital Management, LLC▲ Buy12,871,8002.85%$820.82M2026-08-12
JPMorgan Chase & Co▲ Buy10,329,1642.29%$671.91M2026-08-12
Morgan Stanley▼ Sell6,223,3221.38%$398.36M2026-08-13
Norges Bank▼ Sell5,823,5241.29%$372.76M2026-08-12
Goldman Sachs Group Inc▲ Buy4,446,5650.98%$284.62M2026-08-14
Northern Trust Corp▼ Sell3,938,7480.87%$252.12M2026-08-13
Bank of America Corp▼ Sell3,249,7710.72%$208.02M2026-08-14
FMR LLC (Fidelity)▲ Buy3,155,0950.70%$201.96M2026-08-13
Trian Fund Management, L.P.▲ Buy3,085,3440.68%$197.49M2026-08-12
Temasek Holdings (Private) Ltd▼ Sell2,515,3930.56%$161.01M2026-08-07
Citadel Advisors LLC▲ Buy2,367,0320.52%$151.51M2026-09-02
Point72 Asset Management, L.P.▲ Buy1,165,9730.26%$74.63M2026-08-14
Wells Fargo & Company▼ Sell879,5160.19%$56.30M2026-08-14
Citigroup Inc▲ Buy850,3740.19%$54.43M2026-08-03
AQR Capital Management LLC▲ Buy696,0840.15%$44.33M2026-08-14
Gotham Asset Management, LLC▲ Buy584,3950.13%$37.41M2026-08-14
AllianceBernstein L.P.▼ Sell518,3460.11%$36.90M2026-08-14
Squarepoint Ops LLC▲ Buy446,4310.10%$28.58M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell418,0890.09%$26.76M2026-08-14
Capital Research Global Investors▼ Sell394,1480.09%$25.23M2026-08-12
Susquehanna International Group, LLP▲ Buy314,8670.07%$20.15M2026-08-14
Q2 2026 flow:20.44M sh bought ($1.31B)26.08M sh sold ($1.68B)net -5.64M sh (−$368.10M)
Congressional Trading Activity
7 disclosed trades · ~$56.0K est. traded value · 3 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Terri A. SewellHouseAL07▼ Sell$1K - $15K2026-03-252026-04-21
Warren DavidsonHouseOH08▼ Sell$1K - $15K2026-03-232026-03-25
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Austin ScottHouseGA08▼ Sell$1K - $15K2025-03-272025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27